Denali Therapeutics’ (DNLI) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI) in a research report released on Thursday,Benzinga reports. HC Wainwright currently has a $90.00 price target on the stock. HC Wainwright also issued estimates for Denali Therapeutics’ FY2027 earnings at $1.68 EPS.

DNLI has been the subject of a number of other reports. Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Jefferies Financial Group raised their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Wedbush cut their target price on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Cantor Fitzgerald cut Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Finally, Bank of America increased their price target on Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $38.90.

Denali Therapeutics Price Performance

NASDAQ DNLI traded up $1.75 on Thursday, reaching $31.35. The company had a trading volume of 713,350 shares, compared to its average volume of 1,070,952. The firm has a market capitalization of $4.49 billion, a PE ratio of -10.39 and a beta of 1.40. The firm has a 50-day moving average of $27.67 and a 200-day moving average of $23.40. Denali Therapeutics has a 1 year low of $14.56 and a 1 year high of $32.13.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the business earned ($0.72) EPS. As a group, sell-side analysts expect that Denali Therapeutics will post -2.53 EPS for the current fiscal year.

Insider Buying and Selling

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the sale, the director now owns 29,096 shares in the company, valued at approximately $844,656.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the sale, the director now directly owns 29,096 shares of the company’s stock, valued at approximately $844,656.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Ryan J. Watts sold 40,000 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by insiders.

Institutional Trading of Denali Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new stake in shares of Denali Therapeutics during the third quarter worth $73,000. Swiss National Bank grew its holdings in Denali Therapeutics by 7.7% during the 3rd quarter. Swiss National Bank now owns 250,700 shares of the company’s stock worth $7,303,000 after acquiring an additional 17,900 shares during the period. Thrivent Financial for Lutherans raised its position in shares of Denali Therapeutics by 6.4% in the 3rd quarter. Thrivent Financial for Lutherans now owns 138,862 shares of the company’s stock worth $4,045,000 after acquiring an additional 8,358 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of Denali Therapeutics by 163.7% in the 3rd quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock valued at $1,162,000 after purchasing an additional 24,767 shares during the period. Finally, Assetmark Inc. boosted its position in shares of Denali Therapeutics by 18.0% during the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after purchasing an additional 580 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.